Q4 2025 · 13F-HR
BIOS Capital Management, LPholdings as filed
Filed 2026-02-13 · accession 0001813845-26-000002
$82.6M
Reported value
6
Positions
2025-12-31
Period end
The Brief · BIOS Capital Management, LP · Q4 2025
AI · grounded in 13F
BIOS Capital Management, LP closed its position in INABEUR with a decrease of $622,061. The fund established a new position in INAB valued at $592,996. Additionally, the manager trimmed its holding in LTRN by 0.61%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 005083100 | ACTU | ACTUATE THERAPEUTICS INC | $61.5M | 74.4% | 10,049,996 | Common | SHARED |
| 19243B102 | CGTX | COGNITION THERAPEUTICS INC | $8.1M | 9.80% | 6,000,000 | Common | SHARED |
| 67577R102 | IRD | OPUS GENETICS INC | $7.4M | 8.96% | 3,683,429 | Common | SHARED |
| 51654W101 | LTRN | LANTERN PHARMA INC | $3.1M | 3.70% | 1,009,507 | Common | SHARED |
| 00887A204 | RNTX | REIN THERAPEUTICS INC | $2.0M | 2.37% | 1,690,751 | Common | SHARED |
| 45674E208 | INAB | IN8BIO INC | $592,996 | 0.72% | 253,417 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.